Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)

26.04
Delayed Data
As of Mar 27
 +0.53 / +2.08%
Today’s Change
19.10
Today|||52-Week Range
47.65
+24.36%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$743.2M

Company Description

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It is engaged in the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases. The company's lead product, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. The company was founded by David I. Scheer and William H. Lewis on February 4, 2005 and is headquartered in Cambridge, MA.

Contact Information

Aegerion Pharmaceuticals, Inc.
101 Main Street
Cambridge Massachusetts 02142
P:(617) 500-7867
Investor Relations:
(857) 242-5024

Employees

Shareholders

Other institutional74.64%
Mutual fund holders51.39%
Individual stakeholders38.82%

Top Executives

Marc D. BeerChief Executive Officer & Director
Craig E. FraserChief Operating Officer
Mark J. FitzpatrickChief Financial Officer & Chief Accounting Officer
Diane L. TribbleChief Scientific Officer
Mark SumerayChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account